ALNYLAM PHARMACEUTICALS INC (ALNY)

US02043Q1076 - Common Stock

162.81  +8.07 (+5.22%)

After market: 162.81 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
844.3M
71.29%
1.037B
22.87%
1.828B
76.24%
1.82B
-0.45%
EBITDA
YoY % growth
-661.1M
16.70%
-740.6M
-12.03%
-228.121M
69.20%
-238.444M
-4.53%
EBIT
YoY % growth
-708.7M
14.45%
-785.1M
-10.78%
-282.175M
64.06%
-399.702M
-41.65%
Operating Margin
-83.94%-75.68%-15.43%-21.96%
EPS
YoY % growth
-7.12
7.05%
-8.66
-21.63%
-3.56
58.89%
-4.34
-21.87%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
-1.20
14.46%
Revenue
Q2Q % growth
434.03M
35.93%
EBITDA
Q2Q % growth
-134.922MN/AN/AN/AN/A
EBIT
Q2Q % growth
-119.663M
20.12%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
-1.10
34.52%
-1.350.2518.47%
Q3 2023
Q2Q % growth
1.15
142.75%
-1.362.51184.40%
Q2 2023
Q2Q % growth
-2.21
3.49%
-1.40-0.81-58.30%
Q1 2023
Q2Q % growth
-1.40
30.00%
-1.800.4022.24%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
439.718M
31.26%
451.75M-12.032M-2.66%
Q3 2023
Q2Q % growth
750.5M
183.96%
391.21M359.29M91.84%
Q2 2023
Q2Q % growth
318.8M
41.81%
357.52M-38.72M-10.83%
Q1 2023
Q2Q % growth
319.3M
49.70%
318.5M800K0.25%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS2.67% 2.59% 2.37% 46.13%
Revenue2.89% 1.05% 0% 27.07%